Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone

Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone

The C-C chemokine ligand 2 (CCL2) stimulates migration, proliferation, and invasion of prostate cancer (PCa) cells, and its signaling also plays a role in the activation of osteoclasts. Therefore targeting CCL2 signaling in regulation of tumor progression in bone metastases is an area of intense res...

Full description

Bibliographic Details
Main Authors:	Eva Corey, Robert L. Vessella, Linda A. Snyder, Holly M. Nguyen, Lisha G. Brown, Theodore Koreckij, Peter S. Kirk
Format:	Article
Language:	English
Published:	MDPI AG 2013-05-01
Series:	International Journal of Molecular Sciences
Subjects:	prostate cancer bone metastases chemokine CCL2 docetaxel
Online Access:	http://www.mdpi.com/1422-0067/14/5/10483

Similar Items

Fungal immunomodulatory proteins alleviate docetaxel-induced adverse effects
by: Chu-Chyn Ou, et al.
Published: (2015-12-01)

PROSTATECTOMY FOR METASTATIC PROSTATE CANCER: A CLINICAL CASE
by: V. I. Shirokorad
Published: (2014-07-01)

Clinical case: prostatectomy for metastatic prostate cancer (observation 6 years in the poor prognosis group)
by: V. I. Shirokorad
Published: (2017-04-01)

Cancer of the prostate presenting with diffuse osteolytic metastatic bone lesions: a case report
by: Segamwenge Innocent Lule, et al.
Published: (2012-12-01)

PROSTATECTOMY FOR METASTATIC PROSTATE CANCER: A CLINICAL CASE
by: V. I. Shirokorad
Published: (2014-07-01)

Management of bone metastases in refractory prostate cancer – role of denosumab
by: Paller CJ, et al.
Published: (2012-09-01)

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
by: Soraia Lobo-Martins, et al.
Published: (2020-07-01)

Clinical Study of Docetaxel, Prednisone and Bevacizunab in the Treatment of Hormone Refractory Prostate Cancer
by: Theodore D. Koreckij, et al.
Published: (2015-06-01)

Ra223 in bone metastases with osteolytic activity
by: Renato Patrizio Costa, et al.
Published: (2018-01-01)

Gene expression pattern of CCL2, CCL3, and CXCL8 in patients with bipolar disorder
by: Mohsen Ghoryani, et al.
Published: (2019-01-01)

Prostate cancer bone metastases confined to the distal left lower limb
by: Monique Vekeria, MBBS, BSc (Hons), FRCR, et al.
Published: (2021-09-01)

Advances in Treatment of Patients with Prostate Cancer Bone Metastases
by: LI Ning, et al.
Published: (2020-08-01)

Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France
by: Mathieu Gauthé, et al.
Published: (2020-03-01)

Analysis of orthopedic surgery of bone metastases in breast cancer patients
by: Wegener Bernd, et al.
Published: (2012-11-01)

The Role of Ga-68-PSMA PET/CT in the Initial Staging of Prostate Cancer – A Single Center 4 Year Experience
by: P Lima J, et al.
Published: (2021-07-01)

CCL2 is a Potent Regulator of Prostate Cancer Cell Migration and Proliferation
by: Robert D. Loberg, et al.
Published: (2006-07-01)

Clinical-morphological and laboratory predictors of «superscan» scintigraphy phenomenon in prostate cancer
by: N. Yu. Shumilina, et al.
Published: (2020-04-01)

The role of docetaxel in the multimodal treatment of non-small cell lung cancer
by: Rita De Sanctis, et al.
Published: (2009-06-01)

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
by: Dearbhaile Catherine Collins, et al.
Published: (2020-12-01)

Outcomes of patients with bone metastases from differentiated thyroid cancer
by: Inés Califano, et al.

Prostate cancer in patients from rural and suburban areas – PSA value, Gleason score and presence of metastases in bone scan
by: Wojciech Szot, et al.
Published: (2014-11-01)

Sites of metastasis and overall survival in esophageal cancer: a population-based study
by: Wu SG, et al.
Published: (2017-12-01)

Chemokine CCL4 Induced in Mouse Brain Has a Protective Role against Methylmercury Toxicity
by: Tsutomu Takahashi, et al.
Published: (2018-07-01)

Effect of Pamidronate on Bone Pain in Patients with Bone Metastasis
by: Shahrbanoo Keihanian, et al.
Published: (2013-06-01)

Diagnosis value of prostate specific antigen density (PSAD) and prostate specific antigen (PSA) in bone metastases of prostate cancer among Indonesian population
by: Ahmad Zulfan Hendri, et al.
Published: (2020-05-01)

Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers
by: Wietske I. Luining, et al.
Published: (2021-01-01)

Spinal Stabilization Exercises for Cancer Patients with Spinal Metastases of High Fracture Risk: Feasibility of the DISPO-II Training Program
by: Friederike Rosenberger, et al.
Published: (2021-01-01)

EFFICACY OF ZOLEDRONIC ACID IN THE PREVENTION OF BONE METASTASES IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
by: T. N. Musaev, et al.
Published: (2014-07-01)

ASSESSMENT OF PROGNOSTIC FACTORS CONSIDERING THE VOLUME OF SKELETAL METASTASIS IN PATIENTS WITH DISSEMINATED PROSTATE CANCER
by: N. E. Kosyh, et al.
Published: (2017-03-01)

MINDIN Exerts Protumorigenic Actions on Primary Prostate Tumors via Downregulation of the Scaffold Protein NHERF-1
by: Luis Álvarez-Carrión, et al.
Published: (2021-01-01)

Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients
by: Claire L. Ihle, et al.
Published: (2019-11-01)

The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer
by: Guo X, et al.
Published: (2018-06-01)

EFFICACY OF ZOLEDRONIC ACID IN THE PREVENTION OF BONE METASTASES IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
by: T. N. Musaev, et al.
Published: (2014-07-01)

Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases
by: Flavian Tabotta, et al.
Published: (2019-12-01)

188Re-HEDP therapy in the therapy of painful bone metastases
by: Knut Liepe
Published: (2018-01-01)

Stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic prostate cancer
by: Kamran Ali Ahmed, et al.
Published: (2013-01-01)

A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET)
by: Carole Mercier, et al.
Published: (2019-09-01)

Is femoral uptake of Tc99m-methylene diphosphonate on bone scintigraphy in bronchogenic carcinoma an alarming sign: A case report and brief review of literature?
by: Rayamajhi Sampanna Jung, et al.
Published: (2014-01-01)

INCIDENCE AND CLINICAL CHARACTERISTICS OF BONE METASTASES IN PATIENTS WITH BREAST CARCINOMA
by: Miodrag Projević, et al.
Published: (2003-04-01)

Use of palliative radiotherapy in brain and bone metastases (VARA II study)
by: Expósito Jose, et al.
Published: (2012-08-01)